Table 1.
Baseline characteristics
| Patients given pertuzumab and T-DM1 (n=31) | |
| Age in years | 60 (50.5–68.5) |
| Sex | |
| Men | 24 (77%) |
| Women | 7 (23%) |
| ECOG performance status 0–1 | 31 (100%) |
| HER2 status by IHC and FISH | |
| IHC 3+ | 25 (80%) |
| IHC 2+ | 6 (20 %) |
| FISH + | 31 (100%) |
| Site of primary tumour | |
| Rectum | 12 (39%) |
| Colon | 19 (61%) |
| Proximal* | 2 (10%) |
| Distal† | 17 (90%) |
| Metastatic disease in multiple sites | 24 (77%) |
| Metastatic site | |
| Lung | 25 (80%) |
| Liver | 24 (77%) |
| Lymphnodes | 7 (24%) |
| Others sites | 13 (42%) |
| Number of previous lines of therapy | 3 (3–5) |
| Patients with >4 previous lines of therapy | 15 (48%) |
| Previous anti-angiogenesis treatment | 26 (83%) |
| Previous therapy with panitumumab or cetuximab | 27 (87%) |
Data are n (%) or median (IQR).
*Located in caecum, ascending colon, liver flexure and transverse colon.
†Located in splenic flexure, descending and sigmoid colon.
ECOG, Eastern Cooperative Oncology Group; FISH, fluorescence in situ hybridisation; IHC, immunohistochemistry.